Showing posts with label Sun Pharma. Show all posts
Showing posts with label Sun Pharma. Show all posts

Thursday, February 27, 2020

Tulsi Tanti, Sun Pharma promoters to invest Rs 400 cr in Suzlon Energy

Current Affairs
The advertisers and partners of Suzlon Energy Ltd will mix upto Rs 400 crore as value into the upset sustainable power source area organization through different protections as a feature of an obligation rebuilding plan.
Tanti Holdings Private Limited (advertiser), Shanghvi Finance Pvt. Ltd and partners will implant capital in organization. The top managerial staff, in a late evening gathering on Thursday, endorsed the proposition for rebuilding the organization's obligation and certain distinguished auxiliaries, Suzlon Energy said its documenting with BSE.
Under the endorsed obligation recast plan, the Tulsi Tanti-controlled substance will give protections – shares, convertible bonds and warrants – to 17 banks for changing over of part of obligation into value. A portion of the loan specialists incorporate State Bank of India, Axis Bank, Bank of Baroda, ICICI Bank, IDBI Bank and Yes Bank.
Suzlon stock was administering at Rs 2.6 per share, down 7.42 percent in morning exchanges on BSE.
The Pune-based substance will likewise strip and arrange some of venture, resources and furthermore weaken stake in a portion of the endeavors in accordance with the affirmed arrangement. Be that as it may, the organization didn't indicate resources it would offer to lessen a stake in organizations.

The board likewise affirmed a proposition to designate Sameer Shah as a "Free Director" of the Company for a five-year term initiating February 27. His arrangement is dependent upon regularization by the investors at the following Annual General Meeting of the Company. On giving protections to loan specialists, organization said it will give 100 crore portions of Rs 2 each and furthermore issue 0.041 crore...READ MORE

Tuesday, January 22, 2019

Sun Pharma to settle Dubai firm loans, shift distribution arm to subsidiary

Companies News:

Seeking to ease investor concerns, embattled drug major Sun Pharmaceutical Industries on Tuesday announced plans to unwind loans of Rs 2,238 crore given to a Dubai-based company, Atlas Global Trading FZC, and transfer the distribution of the domestic formulation business to a subsidiary from a separate entity.

Sun Pharma said the company’s consolidated balance sheet had receivables of Rs 2,238 crore from a non-related party. “This liability was in respect of Atlas assuming the damages on account of Protonix patent litigation settlement entered by Sun Pharma, which was disclosed in Sun Pharma’s annual report for fiscal year 2014,” it said in a statement.

Last month, when investors had asked Sun Pharma Managing Director Dilip Shanghvi about the loan in a conference call, he said it was given to a “non-related” party, but did not give details.


 Responding to Business Standard queries, Sun Pharma clarified Atlas Global or any of its subsidiary was not a related party at any point in time...Read More